A recent study reported that BTN3A1-targeted therapy showed superior efficacy to PD-1 checkpoint therapy in validated orthotopic xenograft and syngeneic models of ovarian cancer (17). The gene discussed is PDCD1; the disease is ovarian carcinoma.